Prominent Chronic Spontaneous Urticaria Market Trend for 2025: Development Of Next-Generation Briquilimab (JSP191) To Enhance Treatment Efficacy

What Are the Projected Growth and Market Size Trends for the Chronic Spontaneous Urticaria Market?
The market size for chronic spontaneous urticaria has impressively expanded in the past years. It is projected to increase from $2.06 billion in 2024 to $2.23 billion in 2025, registering a compound annual growth rate (CAGR) of 8.6%. This previous growth can be ascribed to enhancements in diagnostic tools, a rise in awareness amongst healthcare professionals, patient support groups, current studies and clinical trials investigating novel therapies, and an increase in healthcare spending.

Expectations indicate that the market size of chronic spontaneous urticaria will experience substantial growth in the next few years, reaching an estimate of $3.08 billion in 2029, with a compound annual growth rate (CAGR) of 8.4%. This surge in the projected period can be traced back to factors such as the expansion of diagnosed CSU cases, the expansion of patient demographics, development in healthcare infrastructure, conducive regulatory environments, focus on patient-centered care models, and the economic escalation in emerging markets. Technological innovations, progress in biological therapies, evolution of personalized medicine, telemedicine and digital health, advancement in diagnostic tools, AI and machine learning, and an increase in drug approvals and launches, constitute the main trends in the forecasted period.

What Is Contributing to the Growth of the Chronic Spontaneous Urticaria Market?
The growth of the chronic spontaneous urticaria market is predicted to be fueled by the increasing consumption of alcohol. Various factors such as societal norms, stress, promotion tactics, affordability, and accessibility contribute to this uptick in alcohol consumption. The intake of alcohol may aggravate the symptoms of chronic spontaneous urticaria in some individuals, causing an escalation in swelling and hives. For example, rehabs UK, a leading addiction recovery support and advice services provider based in the UK, stated in February 2024 that 55% of men and 41% of women reported consuming alcohol weekly. Furthermore, 8% of men and 5% of women reported almost daily alcohol consumption. During 2021-2022, there were 342,795 hospital admissions solely due to alcohol, equating to a rate of 626 admissions for every 100,000 people. Hence, the growth of the chronic spontaneous urticaria market is propelled by the increasing consumption of alcohol.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Leading Companies Are Shaping the Growth of the Chronic Spontaneous Urticaria Market?
Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

What Are the Major Trends Shaping the Chronic Spontaneous Urticaria Market?
Top-tier firms engaged in the chronic spontaneous urticaria market are pioneering the improved next-generation Briquilimab (JSP191) for better treatment efficiency and less frequent dosages. The next-generation Briquilimab (JSP191) is a monoclonal antibody specifically designed to target and deplete certain immune cells, with a particular focus on CD47 in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., an American clinical-stage biotechnology firm, shared the news of administering its first patient with Briquilimab in a Phase 1b/2a clinical trial for chronic spontaneous urticaria (CSU). This milestone holds significant value in evaluating the safety and performance of Briquilimab, a next-gen monoclonal antibody focusing on CD47, in treating this recurrent issue of hives and itching. The trial's main objective is to determine how effectively Briquilimab can mitigate symptoms and enhance the quality of life for those plagued by CSU.

What Are the Key Segments of the Chronic Spontaneous Urticaria Market?
The chronic spontaneous urticaria market covered in this report is segmented -

1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)
2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy
3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Region Dominates the Chronic Spontaneous Urticaria Market?
North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Chronic Spontaneous Urticaria Global Market Report?

- Market Size Analysis: Analyze the Chronic Spontaneous Urticaria Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Chronic Spontaneous Urticaria Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Chronic Spontaneous Urticaria Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Chronic Spontaneous Urticaria Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.